Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

The future of spatial biology in drug discovery

20 August 2026 · By · Wire by Fusion42

Published

20 August 2026

Topic

opportunities

◆ Sectors

Drug Discovery

◆ Source

Read at drugdiscoverynews.com →

◆ Verified

Fusion42 · 21 August 2026 · Fusion42 review

Spatial biology is expanding beyond oncology into autoimmune diseases, neuroscience, and gene therapy safety, with breakthroughs in spatial transcriptomics, proteomics, and new perturbation-based spatial experiments advancing drug discovery platforms.

This Wire brief sits within Fusion42's coverage of Drug Discovery.

◆ ◆ The Wire takeaway

Spatial biology now offers you a toolkit that reaches beyond cancer into autoimmune and brain diseases with detailed tissue context, turning previously vague cell data into targeted drug discovery paths. Your upcoming projects can exploit spatial experiments combining gene editing and molecular mapping to gain a decisive discovery edge.

◆ Coverage

1 source · 20 Aug 2026

◆ Related on Wire

◆ Topics

Drug Discoveryspatial-biologydrug-discoveryautoimmune-diseaseneurosciencespatial-proteomicsgene-therapy